New Review Highlights How Dermatologists May Better Identify cSCC Patients Who Benefit From Adjuvant Radiation
Have you read this article from the JDD? A new systematic review is drawing attention to one of the most important management questions in cutaneous squamous cell carcinoma which patients with high-risk cSCC are most likely to benefit from adjuvant radiation therapy? For practicing dermatologists and dermatology healthcare professionals, this is an especially relevant issue as cSCC incidence continues to rise and treatment decisions remain highly nuanced.
The review examined published data on clinicopathologic factors and their ability to predict benefit from adjuvant radiation therapy, or ART, in patients with high-risk cSCC. While ART is well established as useful in appropriately selected patients, the authors found that traditional factors alone have important limitations when used to guide treatment decisions. In practice, this can lead to variability in how ART is recommended.
One of the most notable findings is the role of the 40-GEP test in improving risk stratification. According to the review, the 40-GEP assay may help identify patients most likely to benefit from ART, while also helping clinicians consider when ART might reasonably be deferred. The article notes that the Class 2B result is the only high-risk factor shown to predict ART benefit, making this an important point for clinicians managing difficult cSCC cases.
This JDD article offers timely insight into how dermatology teams may refine risk assessment and support more precise treatment planning in cSCC. If you manage patients with high-risk disease, this is one worth reading closely for its potential implications in daily practice.
Blog write-up assisted by AI
